z-logo
open-access-imgOpen Access
SNX16 activates c‐Myc signaling by inhibiting ubiquitin‐mediated proteasomal degradation of eEF1A2 in colorectal cancer development
Author(s) -
Shen Zhiyong,
Li Yongsheng,
Fang Yuan,
Lin Mingdao,
Feng Xiaochuang,
Li Zhenkang,
Zhan Yizhi,
Liu Yuechen,
Mou Tingyu,
Lan Xiaoliang,
Wang Yanan,
Li Guoxin,
Wang Jiping,
Deng Haijun
Publication year - 2020
Publication title -
molecular oncology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.332
H-Index - 88
eISSN - 1878-0261
pISSN - 1574-7891
DOI - 10.1002/1878-0261.12626
Subject(s) - gene knockdown , downregulation and upregulation , cancer research , ubiquitin , ectopic expression , colorectal cancer , carcinogenesis , signal transduction , sorting nexin , ubiquitin ligase , cell growth , biology , microbiology and biotechnology , apoptosis , chemistry , cancer , cell culture , biochemistry , gene , endosome , genetics , intracellular
Sorting nexin 16 (SNX16), a member of the sorting nexin family, has been implicated in tumor development. However, the function of SNX16 has not yet been investigated in colorectal cancer (CRC). Here, we showed that SNX16 expression was significantly upregulated in CRC tissues compared with normal counterparts. Upregulated mRNA levels of SNX16 predicted poor survival of CRC patients. Functional experiments showed that SNX16 could promote CRC cells growth both in vitro and in vivo . Knockdown of SNX16 induced cell cycle arrest and apoptosis, whereas ectopic overexpression of SNX16 had the opposite effects. Mechanistically, SNX16‐eukaryotic translation elongation factor 1A2 (eEF1A2) interaction could inhibit the degradation and ubiquitination of eEF1A2, followed by activation of downstream c‐Myc signaling. Our study unveiled that the SNX16/eEF1A2/c‐Myc signaling axis could promote colorectal tumorigenesis and SNX16 might potentially serve as a novel biomarker for the diagnosis and an intervention of CRC.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.
Having issues? You can contact us here